Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1996 Mar;55(3):169–176. doi: 10.1136/ard.55.3.169

A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis.

G Bendix 1, A Bjelle 1
PMCID: PMC1010123  PMID: 8712879

Abstract

OBJECTIVES: To study the long term tolerance of parenteral gold and subsequent drug treatment in patients with rheumatoid arthritis, including prediction of outcome and 'survival' of sequential treatments. METHODS: A retrospective cohort study of 376 patients was made, including a detailed screening of 237 patients treated in 1989. Reasons for discontinuing treatment were analysed in life table analyses, which were used to compare patients receiving parenteral gold treatment in 1985 and 1989, and two groups of patients receiving disease modifying antirheumatic drugs after parenteral gold treatment. The causes of discontinuation were followed in sequential treatments. RESULTS: The estimated probability of discontinuation of parenteral gold treatment was 29% after six months and 42%, 55%, 74%, and 92% after 1, 2, 5, and 10 years, respectively. Mucocutaneous side effects were the main cause of discontinuation of parenteral gold treatment during the first three years, while the probability of discontinuation because of inefficacy dominated after four years. Side effects also constituted the main cause of discontinuation of treatments given after parenteral gold treatment during the first three years of follow up. No significant differences were found when comparing the termination rates between the first and the second and subsequent treatments after parenteral gold treatment. The main reasons for discontinuing one treatment could not predict the cause of discontinuation of the next treatment. CONCLUSION: Mucocutaneous side effects dominated initially, while inefficacy was the dominating cause of discontinuation of long term parenteral gold treatment. No serious side effects were registered. The cause of discontinuation of one treatment did not predict the cause of discontinuation of the following drug. Drug 'survival' was the same in both treatments after parenteral gold treatment.

Full text

PDF
169

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bendix G., Bjelle A. Outcome of parenteral gold therapy in RA patients: a comparison between two periods using life-table analysis. Br J Rheumatol. 1991 Dec;30(6):407–412. doi: 10.1093/rheumatology/30.6.407. [DOI] [PubMed] [Google Scholar]
  2. Bendix G., Bjelle A. Proresid therapy in rheumatoid arthritis. A comparison with injectable gold using life-table analysis. Scand J Rheumatol. 1993;22(2):77–82. doi: 10.3109/03009749309095119. [DOI] [PubMed] [Google Scholar]
  3. Bretza J., Wells I., Novey H. S. Association of IgE antibodies to sodium aurothiomalate and adverse reactions to chrysotherapy for rheumatoid arthritis. Am J Med. 1983 Jun;74(6):945–950. doi: 10.1016/0002-9343(83)90787-8. [DOI] [PubMed] [Google Scholar]
  4. Capell H. A., Lewis D., Carey J. A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis. Ann Rheum Dis. 1986 Sep;45(9):705–711. doi: 10.1136/ard.45.9.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Capell H. A., Porter D. R., Madhok R., Hunter J. A. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? Ann Rheum Dis. 1993 Jun;52(6):423–428. doi: 10.1136/ard.52.6.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cats A. A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions. 1976 Feb;6(1-3):355–363. doi: 10.1007/BF01972255. [DOI] [PubMed] [Google Scholar]
  7. Cervi P. L., Wright P., Casey E. B. Audit of full blood count monitoring in patients on longterm gold therapy for rheumatoid arthritis. Ir J Med Sci. 1992 Mar;161(3):73–74. doi: 10.1007/BF02983717. [DOI] [PubMed] [Google Scholar]
  8. Clark P., Tugwell P., Bennett K., Bombardier C. Meta-analysis of injectable gold in rheumatoid arthritis. J Rheumatol. 1989 Apr;16(4):442–447. [PubMed] [Google Scholar]
  9. Epstein W. V., Henke C. J., Yelin E. H., Katz P. P. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med. 1991 Mar 15;114(6):437–444. doi: 10.7326/0003-4819-114-6-437. [DOI] [PubMed] [Google Scholar]
  10. Epstein W. V. Parenteral gold therapy for rheumatoid arthritis: a treatment whose time has gone. J Rheumatol. 1989 Oct;16(10):1291–1294. [PubMed] [Google Scholar]
  11. Felson D. T., Anderson J. J., Meenan R. F. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum. 1992 Oct;35(10):1117–1125. doi: 10.1002/art.1780351003. [DOI] [PubMed] [Google Scholar]
  12. Fraser T. N. Gold Treatment in Rheumatoid Arthritis. Ann Rheum Dis. 1945 Jun;4(4):71–75. doi: 10.1136/ard.4.4.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fries J. F., Williams C. A., Ramey D., Bloch D. A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum. 1993 Mar;36(3):297–306. doi: 10.1002/art.1780360303. [DOI] [PubMed] [Google Scholar]
  14. Harth M., Davis P., Thompson J. M., Menard H., Beaudet F. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis. Results of a two-year open randomized study. Scand J Rheumatol. 1987;16(3):177–184. doi: 10.3109/03009748709165271. [DOI] [PubMed] [Google Scholar]
  15. Harth M. Gold in rheumatoid arthritis: standard, substitute or sham? J Rheumatol. 1993 May;20(5):771–773. [PubMed] [Google Scholar]
  16. Husain Z., Runge L. A. Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine, and levamisole. J Rheumatol. 1980 Nov-Dec;7(6):825–830. [PubMed] [Google Scholar]
  17. Jessop J. D. Gold in the treatment of rheumatoid arthritis -- why, when and how? J Rheumatol Suppl. 1979;5:12–17. [PubMed] [Google Scholar]
  18. Kean W. F., Anastassiades T. P. Long term chrysotherapy: incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum. 1979 May;22(5):495–501. doi: 10.1002/art.1780220509. [DOI] [PubMed] [Google Scholar]
  19. Lockie L. M., Smith D. M. Forty-seven years experience with gold therapy in 1,019 rheumatoid arthritis patients. Semin Arthritis Rheum. 1985 May;14(4):238–246. doi: 10.1016/0049-0172(85)90043-5. [DOI] [PubMed] [Google Scholar]
  20. Luukkainen R. Chrysotherapy in rheumatoid arthritis with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy. Scand J Rheumatol Suppl. 1980;34:1–56. [PubMed] [Google Scholar]
  21. Merck C., Angervall L., Kindblom L. G., Odén A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl. 1983;282:1–40. [PubMed] [Google Scholar]
  22. Mitchell D. M., Spitz P. W., Young D. Y., Bloch D. A., McShane D. J., Fries J. F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986 Jun;29(6):706–714. doi: 10.1002/art.1780290602. [DOI] [PubMed] [Google Scholar]
  23. Morand E. F., McCloud P. I., Littlejohn G. O. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol. 1992 May;19(5):704–708. [PubMed] [Google Scholar]
  24. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Pinals R. S., Masi A. T., Larsen R. A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981 Oct;24(10):1308–1315. doi: 10.1002/art.1780241012. [DOI] [PubMed] [Google Scholar]
  26. Pincus T., Callahan L. F., Sale W. G., Brooks A. L., Payne L. E., Vaughn W. K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984 Aug;27(8):864–872. doi: 10.1002/art.1780270805. [DOI] [PubMed] [Google Scholar]
  27. Pincus T., Marcum S. B., Callahan L. F. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992 Dec;19(12):1885–1894. [PubMed] [Google Scholar]
  28. Pullar T., Hunter J. A., Capell H. A. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J (Clin Res Ed) 1983 Oct 15;287(6399):1102–1104. doi: 10.1136/bmj.287.6399.1102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  30. Rothermich N. O., Philips V. K., Bergen W., Thomas M. H. Followup study of chrysotherapy. Arthritis Rheum. 1979 Apr;22(4):423–423. doi: 10.1002/art.1780220418. [DOI] [PubMed] [Google Scholar]
  31. Scott D. L., Symmons D. P., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987 May 16;1(8542):1108–1111. doi: 10.1016/s0140-6736(87)91672-2. [DOI] [PubMed] [Google Scholar]
  32. Sigler J. W., Bluhm G. B., Duncan H., Sharp J. T., Ensign D. C., McCrum W. R. Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann Intern Med. 1974 Jan;80(1):21–26. doi: 10.7326/0003-4819-80-1-21. [DOI] [PubMed] [Google Scholar]
  33. Situnayake R. D., Grindulis K. A., McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987 Mar;46(3):177–183. doi: 10.1136/ard.46.3.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Srinivasan R., Miller B. L., Paulus H. E. Long-term chrysotherapy in rheumatoid arthritis. Arthritis Rheum. 1979 Feb;22(2):105–110. doi: 10.1002/art.1780220201. [DOI] [PubMed] [Google Scholar]
  35. Ward J. R., Williams H. J., Egger M. J., Reading J. C., Boyce E., Altz-Smith M., Samuelson C. O., Jr, Willkens R. F., Solsky M. A., Hayes S. P. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983 Nov;26(11):1303–1315. doi: 10.1002/art.1780261102. [DOI] [PubMed] [Google Scholar]
  36. Ward M. M., Leigh J. P., Fries J. F. Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care. Arch Intern Med. 1993 Oct 11;153(19):2229–2237. [PubMed] [Google Scholar]
  37. Watkins P. B., Schade R., Mills A. S., Carithers R. L., Jr, Van Thiel D. H. Fatal hepatic necrosis associated with parenteral gold therapy. Dig Dis Sci. 1988 Aug;33(8):1025–1029. doi: 10.1007/BF01536001. [DOI] [PubMed] [Google Scholar]
  38. Wijnands M. J., van't Hof M. A., van Leeuwen M. A., van Rijswijk M. H., van de Putte L. B., van Riel P. L. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol. 1992 Apr;31(4):253–258. doi: 10.1093/rheumatology/31.4.253. [DOI] [PubMed] [Google Scholar]
  39. Williams H. J., Ward J. R., Dahl S. L., Clegg D. O., Willkens R. F., Oglesby T., Weisman M. H., Schlegel S., Michaels R. M., Luggen M. E. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum. 1988 Jun;31(6):702–713. doi: 10.1002/art.1780310602. [DOI] [PubMed] [Google Scholar]
  40. Wolfe F., Hawley D. J., Cathey M. A. Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy. J Rheumatol. 1993 May;20(5):797–802. [PubMed] [Google Scholar]
  41. Wolfe F., Hawley D. J., Cathey M. A. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol. 1990 Aug;17(8):994–1002. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES